Wyeth-Ayerst.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 97
- Publication type:
- Article
Works matching IS 1082801X AND DT 2000 AND VI 35 AND IP 10
Results: 27
1
2
Schering-Plough.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 92
- Publication type:
- Article
3
Sanofi-Synthelabo.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 88
- Publication type:
- Article
4
Roche.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 83
- Publication type:
- Article
5
Pharmacia Corporation.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 77
- Publication type:
- Article
6
Pfizer.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 71
- Publication type:
- Article
7
Novartis.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 63
- Publication type:
- Article
8
Merck.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 59
- Publication type:
- Article
9
Lilly.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 54
- Publication type:
- Article
10
Johnson & Johnson.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 49
- Publication type:
- Article
11
GlaxoSmithKline.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 39
- Publication type:
- Article
12
Bristol-Myers Squibb.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 32
- Publication type:
- Article
13
Boehringer Ingelheim.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 28
- Publication type:
- Article
14
Bayer Corporation.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 25
- Publication type:
- Article
15
Aventis.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 19
- Publication type:
- Article
16
AstraZeneca.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 10
- Publication type:
- Article
17
Abbott Laboratories.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 5
- Publication type:
- Article
18
New neuraminidase inhibitors for influenza: current and potential therapeutic roles.
- Published in:
- 2000
- By:
- Publication type:
- Journal Article
19
Nateglinide: a new member of the meglitinide family for postprandial glucose control in type 2 diabetes.
- Published in:
- 2000
- By:
- Publication type:
- Journal Article
20
Drug Watch.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 858
- Publication type:
- Article
21
Public concerns for patient safety prompt changes in clinical trial policies.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 853
- By:
- Publication type:
- Article
22
Software-aided evaluation of antibiotic cost and coverage: Example of empiric therapy for intraperitoneal abscess infections.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 842
- By:
- Publication type:
- Article
23
How to use multiple logistic regression in retrospective database analyses.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 832
- By:
- Publication type:
- Article
24
New neuraminidase inhibitors for influenza: Current and potential therapeutic roles.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 812
- By:
- Publication type:
- Article
25
Nateglinide A new member of the meglitinide family for postprandial glucose control in type 2 diabetes.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 798
- By:
- Publication type:
- Article
26
News Capsules.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 797
- Publication type:
- Article
27
FDA Drug Approvals.
- Published in:
- Formulary, 2000, v. 35, n. 10, p. 791
- Publication type:
- Article